Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN-4: Neoadjuvant Tucatinib, Trastuzumab, and Pertuzumab in HER2+ Breast Cancer
NCT06162559Phase 1Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tucatinib in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence and severity of adverse events at 8 months. Started Dec 2023; status: recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06162559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162559.